IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by WASHINGTON TRUST Co

WASHINGTON TRUST Co lessened its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 2.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 101,414 shares of the medical research company’s stock after selling 2,540 shares during the quarter. WASHINGTON TRUST Co owned 0.06% of IQVIA worth $19,929,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Smith Group Asset Management LLC acquired a new stake in IQVIA in the 4th quarter valued at approximately $1,616,000. Simplify Asset Management Inc. boosted its position in shares of IQVIA by 67.8% during the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after buying an additional 3,894 shares during the period. Nordea Investment Management AB raised its holdings in shares of IQVIA by 47.4% in the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after buying an additional 452,029 shares during the period. Fifth Third Bancorp lifted its stake in IQVIA by 13.0% during the 4th quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock worth $2,590,000 after acquiring an additional 1,521 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after acquiring an additional 583,396 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently issued reports on IQV shares. Royal Bank of Canada reissued an “outperform” rating and set a $270.00 price target on shares of IQVIA in a research report on Monday, February 10th. BTIG Research cut shares of IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. Robert W. Baird cut their price objective on IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 21st. Truist Financial reiterated a “buy” rating and issued a $263.00 target price (up from $261.00) on shares of IQVIA in a report on Monday, February 10th. Finally, Barclays cut their price target on IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd. Five research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $251.67.

IQVIA Trading Down 1.2 %

IQV opened at $193.65 on Friday. The business’s 50 day moving average is $200.59 and its two-hundred day moving average is $218.51. The firm has a market cap of $35.15 billion, a price-to-earnings ratio of 25.82, a price-to-earnings-growth ratio of 2.25 and a beta of 1.48. IQVIA Holdings Inc. has a 52 week low of $187.62 and a 52 week high of $261.73. The company has a quick ratio of 0.81, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, research analysts predict that IQVIA Holdings Inc. will post 10.81 EPS for the current year.

Insider Buying and Selling at IQVIA

In other news, Director John G. Danhakl acquired 1,275 shares of the stock in a transaction that occurred on Tuesday, December 3rd. The shares were purchased at an average cost of $200.58 per share, for a total transaction of $255,739.50. Following the transaction, the director now directly owns 1,275 shares in the company, valued at approximately $255,739.50. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. 1.60% of the stock is owned by company insiders.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.